LaFleur & Godfrey LLC Buys 15,692 Shares of Abbott Laboratories (NYSE:ABT)

LaFleur & Godfrey LLC increased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 23.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,443 shares of the healthcare product maker's stock after purchasing an additional 15,692 shares during the period. Abbott Laboratories accounts for about 1.3% of LaFleur & Godfrey LLC's investment portfolio, making the stock its 29th largest holding. LaFleur & Godfrey LLC's holdings in Abbott Laboratories were worth $9,325,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Groupama Asset Managment raised its stake in shares of Abbott Laboratories by 22.2% in the 3rd quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker's stock valued at $26,000 after acquiring an additional 41,557 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new position in shares of Abbott Laboratories during the third quarter worth approximately $31,000. Itau Unibanco Holding S.A. acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth about $32,000. Peterson Financial Group Inc. acquired a new stake in shares of Abbott Laboratories during the third quarter worth about $32,000. Finally, Valued Wealth Advisors LLC raised its holdings in Abbott Laboratories by 78.4% during the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker's stock worth $33,000 after buying an additional 127 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ABT has been the subject of several research reports. Royal Bank of Canada increased their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 8th. UBS Group raised their price objective on Abbott Laboratories from $143.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Piper Sandler increased their price target on Abbott Laboratories from $131.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, October 17th. Barclays upped their price target on shares of Abbott Laboratories from $143.00 to $149.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Evercore ISI raised their target price on shares of Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research note on Thursday, January 2nd. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $131.57.

Abbott Laboratories Price Performance

ABT stock traded down $0.46 during mid-day trading on Monday, hitting $113.45. The stock had a trading volume of 6,443,213 shares, compared to its average volume of 4,199,178. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $121.64. The firm has a fifty day simple moving average of $114.93 and a 200 day simple moving average of $112.87. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $196.78 billion, a P/E ratio of 34.48, a P/E/G ratio of 2.40 and a beta of 0.73.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a yield of 2.08%. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. Abbott Laboratories's dividend payout ratio (DPR) is currently 66.87%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.